Improving health care access for all Ghanaians
Akoma Pa
Non-communicable diseases (NCDs), especially cardiovascular diseases, are a leading cause of death in sub-Saharan Africa. In Ghana, approximately half of the population suffers from hypertension. Less than a third of those who are ill have been diagnosed, and just 22 per cent of patients are receiving treatment. About half of all deaths (43 per cent) are due to NCDs. Increasingly, common complications related to the absence of diagnosis and treatment are also a factor. A similar picture can be seen for diabetes.
In response to the situation, in 2021 CHAG began the “Akomapa” (healthy heart) project. focuses on improving the diagnosis, control, and treatment of patients with hypertension and/or diabetes to minimise life-threatening complications and increase the quality of life in rural Ghana. The project aims to improve the local diagnosis and treatment of these diseases in 85 facilities in rural communities to achieve the broadest possible delivery of health care.
It concentrates on better and early diagnosis to prevent subsequent complications of the primary diseases. As at December 2021, the project had recruited nearly 8,000 clients with over 50% achieving good control.
Project Partners

CHAG launches “Akoma Pa" project
The programme was officially launched at St. Michael Hospital, one of the 85 selected health facilities across the country chosen to implement the project and support the delivery of screening, treatment, and follow-up care services to beneficiaries.

CHAG provides free medical screening and treatment
The CHAG and medical diagnostic giant Medtronic Labs have begun a project to screen and give free medical assistance to 75,000 Ghanaians living with hypertension and diabetes in rural communities across the country.

Akoma Pa, Healthcare For Patients with Diabetes and Hypertension Launch
Medtronic LABS has partnered with CHAG, Ghana’s second-largest health care provider with 1140 healthcare and training facilities across the country, as well as Novartis SSA, BMZ for financing, and implementation support by (GIZ) GmbH.
